Program: Celiac disease
Barinthus Biotherapeutics rights: Worldwide
Upcoming Milestones: Filing of IND application in H2 2023
It is estimated that 1.4 in 100 people worldwide suffer from celiac disease. There are currently no therapies for celiac disease approved by national health regulatory authorities around the world. Patients suffering from celiac are advised to maintain a strict gluten free diet with the potential for even small amounts of gluten contamination to cause severe side effects.
VTP-1000 is an antigen-specific immunotherapy utilizing the SNAP Tolerance Platform co-delivering gluten antigens and a mTor inhibitor to induce regulatory T cells to return the immune system to normal.
VTP-1000 is the first candidate being advanced to the clinic using the SNAP Tolerance Platform. To date, the platform has shown compelling mechanistic and PK/PD data and demonstrated preclinical activity in experimental autoimmune encephalomyelitis in models in mice.
- Singh P, et al, Clin Gastroenterol Hepatol. 2018 Mar 16(6):823-36